Brain HealthOzempic Cuts Depression and Anxiety Risk by Up to 44% in Landmark Study
A large Swedish study tracking nearly 100,000 people over 13 years found that GLP-1 drugs like semaglutide — the active ingredient in Ozempic and Wegovy — are linked to dramatic reductions in depression, anxiety, substance use disorders, and suicidal behavior. During periods of semaglutide use, psychiatric hospital visits and sick leave dropped by 42%, depression risk fell 44%, and anxiety disorders decreased 38%. Researchers from the University of Eastern Finland, Karolinska Institutet, and Griffith University suggest the benefits may stem from weight loss, improved blood sugar control, reduced alcohol use, and possibly direct neurobiological effects on the brain. The findings add a compelling mental health dimension to an already blockbuster class of metabolic drugs.
